BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

483 related articles for article (PubMed ID: 31857207)

  • 1. Biologics and Bronchial Thermoplasty for severe refractory asthma treatment: From eligibility criteria to real practice. A cross-sectional study.
    Menzella F; Galeone C; Ruggiero P; Bagnasco D; Catellani C; Facciolongo N
    Pulm Pharmacol Ther; 2020 Feb; 60():101874. PubMed ID: 31857207
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Biologic treatment eligibility for real-world patients with severe asthma: The IDEAL study.
    Albers FC; Müllerová H; Gunsoy NB; Shin JY; Nelsen LM; Bradford ES; Cockle SM; Suruki RY
    J Asthma; 2018 Feb; 55(2):152-160. PubMed ID: 28622052
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Switching from omalizumab to mepolizumab: real-life experience from Southern Italy.
    Carpagnano GE; Pelaia C; D'Amato M; Crimi N; Scichilone N; Scioscia G; Resta O; Calabrese C; Pelaia G; Quarato CMI; Foschino Barbaro MP
    Ther Adv Respir Dis; 2020; 14():1753466620929231. PubMed ID: 32482128
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Real-World Evaluation of Clinical Outcomes of Biologicals and Bronchial Thermoplasty for Severe Refractory Asthma (BIOTERM).
    Menzella F; Fontana M; Galeone C; D'Amato M; Canonica GW; Ghidoni G; Capobelli S; Scelfo C; Simonazzi A; Catellani C; Ruggiero P; Facciolongo N
    J Asthma Allergy; 2021; 14():1019-1031. PubMed ID: 34413654
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Significant improvement in lung function and asthma control after benralizumab treatment for severe refractory eosinophilic asthma.
    Menzella F; Ruggiero P; Galeone C; Scelfo C; Bagnasco D; Facciolongo N
    Pulm Pharmacol Ther; 2020 Oct; 64():101966. PubMed ID: 33039666
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The clinical profile of benralizumab in the management of severe eosinophilic asthma.
    Menzella F; Lusuardi M; Galeone C; Facciolongo N; Zucchi L
    Ther Adv Respir Dis; 2016 Dec; 10(6):534-548. PubMed ID: 27612492
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of treatment with biologicals (benralizumab, dupilumab, mepolizumab, omalizumab and reslizumab) for severe eosinophilic asthma. A systematic review for the EAACI Guidelines - recommendations on the use of biologicals in severe asthma.
    Agache I; Beltran J; Akdis C; Akdis M; Canelo-Aybar C; Canonica GW; Casale T; Chivato T; Corren J; Del Giacco S; Eiwegger T; Firinu D; Gern JE; Hamelmann E; Hanania N; Mäkelä M; Hernández-Martín I; Nair P; O'Mahony L; Papadopoulos NG; Papi A; Park HS; Pérez de Llano L; Posso M; Rocha C; Quirce S; Sastre J; Shamji M; Song Y; Steiner C; Schwarze J; Alonso-Coello P; Palomares O; Jutel M
    Allergy; 2020 May; 75(5):1023-1042. PubMed ID: 32034960
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Upper and lower airway inflammation in severe asthmatics: a guide for a precision biologic treatment.
    Latorre M; Bacci E; Seccia V; Bartoli ML; Cardini C; Cianchetti S; Cristofani L; Di Franco A; Miccoli M; Puxeddu I; Celi A; Paggiaro P
    Ther Adv Respir Dis; 2020; 14():1753466620965151. PubMed ID: 33263506
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical and histopathologic predictors of therapeutic response to bronchial thermoplasty in severe refractory asthma.
    Ladjemi MZ; Di Candia L; Heddebaut N; Techoueyres C; Airaud E; Soussan D; Dombret MC; Hamidi F; Guillou N; Mordant P; Castier Y; Létuvé S; Taillé C; Aubier M; Pretolani M
    J Allergy Clin Immunol; 2021 Nov; 148(5):1227-1235.e6. PubMed ID: 33453288
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety of Biological Therapies for Severe Asthma: An Analysis of Suspected Adverse Reactions Reported in the WHO Pharmacovigilance Database.
    Cutroneo PM; Arzenton E; Furci F; Scapini F; Bulzomì M; Luxi N; Caminati M; Senna G; Moretti U; Trifirò G
    BioDrugs; 2024 May; 38(3):425-448. PubMed ID: 38489062
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical characteristics of complete responders versus non-complete responders to omalizumab, benralizumab and mepolizumab in patients with severe asthma: a long-term retrospective analysis.
    Basagaña M; Martínez-Rivera C; Padró C; Garcia-Olivé I; Martínez-Colls M; Navarro J; Pardo L; Cruz P; Cardona Peitx G; Carabias L; Roger A; Abad J; Rosell A
    Ann Med; 2024 Dec; 56(1):2317356. PubMed ID: 38364218
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical Characteristics of Severe Refractory Asthma Associated with the Effectiveness of Bronchial Thermoplasty.
    Minami D; Kayatani H; Sato K; Fujiwara K; Shibayama T; Yonei T; Sato T
    Acta Med Okayama; 2019 Apr; 73(2):155-160. PubMed ID: 31015750
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Real-Life Effectiveness of Benralizumab, Mepolizumab and Omalizumab in Severe Allergic Asthma Associated with Nasal Polyps.
    Tiotiu A; Mendez-Brea P; Ioan I; Romero-Fernandez R; Oster JP; Hoang TC; Roux P; Ochoa-Gutierrez DC; Bonniaud P; de Blay F; Gonzalez-Barcala FJ
    Clin Rev Allergy Immunol; 2023 Apr; 64(2):179-192. PubMed ID: 35420388
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Guiding principles for use of newer biologics and bronchial thermoplasty for patients with severe asthma.
    Blaiss MS; Castro M; Chipps BE; Zitt M; Panettieri RA; Foggs MB
    Ann Allergy Asthma Immunol; 2017 Dec; 119(6):533-540. PubMed ID: 29103801
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Biologicals in the Treatment of Bronchial Asthma].
    Haasler I; Taube C
    Pneumologie; 2017 Oct; 71(10):684-698. PubMed ID: 29017221
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Severe asthma and eligibility for biologics in a Brazilian cohort.
    Marques Mello L; Viana KP; Moraes Dos Santos F; Saturnino LTM; Kormann ML; Lazaridis E; Torreão CD; Soares CR; Abreu GA; Lima VB; Pinheiro GP; Lima-Matos A; Ponte EV; Mohan D; Riley JH; Cruz AA
    J Asthma; 2021 Jul; 58(7):958-966. PubMed ID: 32270729
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of omalizumab and mepolizumab treatment efficacy in patients with atopic and eosinophilic "Overlap" severe asthma: Biological agent preference in atopic-eosinophilic severe asthma.
    Tepetam FM; Akyildiz AB; Özden Ş; Örcen C; Yakut T; Atik Ö
    Medicine (Baltimore); 2023 May; 102(18):e33660. PubMed ID: 37144999
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rapid Effect of Benralizumab for Hypereosinophilia in a Case of Severe Asthma with Eosinophilic Chronic Rhinosinusitis.
    Tsurumaki H; Matsuyama T; Ezawa K; Koga Y; Yatomi M; Aoki-Saito H; Chikamatsu K; Hisada T
    Medicina (Kaunas); 2019 Jul; 55(7):. PubMed ID: 31277327
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Smaller Differences in the Comparative Effectiveness of Biologics in Reducing Asthma-Related Hospitalizations Compared With Overall Exacerbations.
    Akenroye A; Marshall J; Simon AL; Hague C; Costa R; Jamal-Allial A; McMahill-Walraven CN; Haffenreffer K; Han A; Wu AC
    J Allergy Clin Immunol Pract; 2024 Jun; 12(6):1568-1574.e2. PubMed ID: 38431251
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Improvement in Olfaction in Patients With CRSwNP and Severe Asthma Taking Anti-IgE and Anti-IL-5 Biologics: A Real-Life Study.
    Barroso B; Valverde-Monge M; Alobid I; Olaguibel JM; Rial MJ; Quirce S; Arismendi E; Barranco P; Betancor D; Bobolea I; Cárdaba B; Cruz Carmona MJ; Curto E; Domínguez-Ortega J; González-Barcala FJ; Martínez-Rivera C; Mahíllo-Fernández I; Muñoz X; Picado C; Plaza V; Rodrigo Muñoz JM; Soto-Retes L; Valero A; Del Pozo V; Mullol J; Sastre J
    J Investig Allergol Clin Immunol; 2023 Feb; 33(1):37-44. PubMed ID: 35416154
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.